Insmed, Inc. $INSM Stock Acquired by Candriam S.C.A.

Candriam S.C.A. boosted its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 4.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 581,069 shares of the biopharmaceutical company’s stock after acquiring an additional 25,938 shares during the period. Candriam S.C.A. owned 0.26% of Insmed worth $66,566,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in INSM. Ethic Inc. increased its stake in Insmed by 109.9% in the 3rd quarter. Ethic Inc. now owns 10,498 shares of the biopharmaceutical company’s stock worth $1,198,000 after acquiring an additional 5,496 shares during the last quarter. Pictet Asset Management Holding SA grew its holdings in Insmed by 44.0% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,757,541 shares of the biopharmaceutical company’s stock valued at $200,845,000 after purchasing an additional 537,188 shares during the last quarter. AlphaCentric Advisors LLC raised its holdings in shares of Insmed by 4.2% in the third quarter. AlphaCentric Advisors LLC now owns 12,195 shares of the biopharmaceutical company’s stock worth $1,392,000 after buying an additional 496 shares during the period. Parallel Advisors LLC lifted its position in shares of Insmed by 5.4% during the third quarter. Parallel Advisors LLC now owns 2,275 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 117 shares during the last quarter. Finally, CenterBook Partners LP lifted its position in shares of Insmed by 10.2% during the third quarter. CenterBook Partners LP now owns 113,720 shares of the biopharmaceutical company’s stock worth $12,980,000 after purchasing an additional 10,569 shares during the last quarter.

Analysts Set New Price Targets

A number of research analysts have recently commented on INSM shares. Jefferies Financial Group restated a “buy” rating and issued a $175.00 price target on shares of Insmed in a report on Thursday, August 6th. Roth Capital reiterated a “buy” rating and set a $198.00 price objective (down from $212.00) on shares of Insmed in a report on Tuesday, September 15th. Guggenheim lowered their price objective on shares of Insmed from $205.00 to $201.00 and set a “buy” rating for the company in a research report on Monday, November 2nd. The Goldman Sachs Group started coverage on shares of Insmed in a research note on Thursday, September 24th. They issued a “buy” rating and a $188.00 target price on the stock. Finally, Mizuho set a $154.00 target price on shares of Insmed in a research report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $196.52.

Insmed Stock Performance

Shares of Insmed stock opened at $114.40 on Friday. The company has a market capitalization of $25.10 billion, a PE ratio of -40.57 and a beta of 0.83. The company has a 50-day simple moving average of $111.21 and a two-hundred day simple moving average of $124.36. Insmed, Inc. has a one year low of $90.39 and a one year high of $212.75. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.59 and a current ratio of 2.86.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The firm had revenue of $524.43 million during the quarter, compared to the consensus estimate of $500.36 million. Insmed had a negative net margin of 39.85% and a negative return on equity of 96.38%. The firm’s quarterly revenue was up 268.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.75) earnings per share. Research analysts expect that Insmed, Inc. will post -1.86 EPS for the current fiscal year.

Insider Activity

In other Insmed news, COO Roger Adsett sold 239,850 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $133.27, for a total value of $31,964,809.50. Following the completion of the transaction, the chief operating officer owned 98,744 shares in the company, valued at $13,159,612.88. This represents a 70.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director David R. Brennan sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the sale, the director owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. This represents a 38.92% decrease in their position. The SEC filing for this sale provides additional information. 2.10% of the stock is currently owned by insiders.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr.

Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.